EBITDA Margin % is calculated as EBITDA divided by its Revenue. Hansa Biopharma AB's EBITDA for the
three
months ended in Mar. 2026 was kr-140.0 Mil. Hansa Biopharma AB's Revenue for the
three
months ended in Mar. 2026 was kr34.6 Mil. Therefore, Hansa Biopharma AB's EBITDA margin for the quarter that ended in Mar. 2026 was -404.83%.
Hansa Biopharma AB (OSTO:HNSA) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Hansa Biopharma AB EBITDA Margin % Related Terms
Hansa Biopharma AB EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Hansa Biopharma AB's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:HNSA vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Hansa Biopharma AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hansa Biopharma AB EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hansa Biopharma AB's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Hansa Biopharma AB's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hansa Biopharma AB (OSTO:HNSA) has a EBITDA Margin % of -404.83% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Hansa Biopharma AB and its competitors. According to the industry distribution chart, Hansa Biopharma AB ranks #619 out of 944 companies in the Biotechnology industry, placing it in the top 65.6%.
Is Hansa Biopharma AB's EBITDA Margin % too high?
Hansa Biopharma AB's current EBITDA Margin % is -404.83%. Based on the distribution chart, Hansa Biopharma AB ranks #619 out of 944 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Hansa Biopharma AB has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hansa Biopharma AB's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Hansa Biopharma AB ranks #619 out of 944 companies for EBITDA Margin %. This places Hansa Biopharma AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Hansa Biopharma AB and its competitors. Hansa Biopharma AB's current EBITDA Margin % is -404.83%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hansa Biopharma AB stock overvalued right now?
Based on GuruFocus' analysis, Hansa Biopharma AB (OSTO:HNSA) is currently considered Significantly Overvalued. The stock's GF Value™ is kr24.55, compared to a current price of kr33.52 — trading 36.5% above its estimated fair value. The current EBITDA Margin % is -404.83%. Hansa Biopharma AB's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Hansa Biopharma AB (OSTO:HNSA), the current EBITDA Margin % is -404.83% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hansa Biopharma AB (OSTO:HNSA) Overvalued in 2026?
Based on GuruFocus' analysis, Hansa Biopharma AB stock appears to be overvalued.
The current stock price of kr33.52 is trading 36.5% above its estimated GF Value™ of kr24.55.
GuruFocus considers Hansa Biopharma AB to be Significantly Overvalued.
Key valuation signals for OSTO:HNSA:
EBITDA Margin %: -404.83%
GF Value™: kr24.55 vs. price of kr33.52 (36.5% above fair value)
No single metric tells the full story. See the OSTO:HNSA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hansa Biopharma AB is a commercial-stage biopharmaceutical company pioneering the development and commercialization of life-saving and life-altering therapies for patients with rare immunological conditions. It has developed a proprietary, first-in-class antibody-cleaving enzyme technology platform designed to eliminate pathogenic IgG antibodies. This differentiated platform supports a broad pipeline with potential applications across Transplantation, Autoimmune diseases, and Gene Therapy-areas characterized by unmet medical need. Hansa's first-generation IgG-cleaving enzyme, imlifidase, is designed to inactivate all four IgG subclasses (IgG1, IgG2, IgG3, and IgG4) in both the intravascular and extravascular compartments following a single intravenous administration.
49GF Score
Get the complete analysis for OSTO:HNSA
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:HNSA has been successfully added to your 
